Literature DB >> 11202964

For debate: concomitant critical coronary arterial disease and abdominal aortic aneurysm--timing of corrective procedures.

M Onwudike1, M Barnard, R Singh-Ranger, M Raphael, M Adiseshiah.   

Abstract

BACKGROUND: The high prevalence of coronary artery disease (CAD) in patients with abdominal aortic aneurysm (AAA) is responsible for most , 30-day mortality and morbidity in elective repair of AAA. The continuing debate regarding staged or combined surgery for AAA and CAD (coronary artery bypass grafting -CABG) in the small number of patients with critical degrees of both co-morbidities has not had a significant impact on the greater mortality and morbidity when the AAA repair is undertaken using the standard open operation. PATIENTS: We report four cases with these combined pathologies which we have managed over the last 30 months during which time we have developed techniques of endolumenal repair of AAA.
CONCLUSIONS: Whilst it is not possible to make firm recommendations regarding management strategy owing mainly to a lack of large series reporting this unusual combination of co-morbidities, the options are debated on the basis of published anecdotal evidence as well as our own case reports. We suggest that if the AAA is non-tender and/or 5.5-8.0 cm, the staged approach is appropriate. If the AAA is tender and/or > 8.0 cm, a combined approach may be a better option in order to avoid the risk of AAA rupture during the interval between the operations. Endolumenal repair of AAA offers a further option for the staged and combined approach, and may be less invasive than the standard open surgery for AAA repair.

Entities:  

Mesh:

Year:  2000        PMID: 11202964     DOI: 10.1016/s0967-2109(00)00037-5

Source DB:  PubMed          Journal:  Cardiovasc Surg        ISSN: 0967-2109


  1 in total

1.  A Case of Simultaneous Endovascular Aneurysmal Repair (EVAR) and Coronary Artery Bypass Grafting (CABG).

Authors:  Shun-Ichi Kawarai; Gen-Ya Yaginuma; Kazuo Abe
Journal:  Ann Vasc Dis       Date:  2012-10-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.